Spondyloarthritis (NEW!!!)


Biomedcode has recently added in its collection of unique animal models of human disease the TgA86 mouse model spontaneously developing spondyloarthritis due to the overexpression of mouse transmembrane  TNF. An efficacy evaluation platform is under development to allow the evaluation of specific spondyloarthritis  therapeutics.

Spondyloarthritis (SpA) is a category of chronic inflammatory arthritides characterized by inflammation and structural damage accompanied by new bone formation. Its subforms include ankylosing spondylitis, psoriatic arthritis, enteropathic spondyloarthritis, reactive arthritis and undifferentiated spondyloarthritis that are characterized by both axial and peripheral joint damage distinct in nature from that observed in Rheumatoid Arthritis as, apart from bone and cartilage damage, pathology includes the formation of pathological new bone that gradually leads to joint ankylosis. Therapeutic blockade of TNF has beneficial impact on the pathology of the different SpA subforms.


1. Baeten D., Breban M., Lories R., Schett G. and Sieper J. 2013 “Are Spondylarthritides Related but Distinct Conditions or a Single Disease With a Heterogeneous Phenotype?” Arthritis Rheum. 65, 12–20. (View article)

2. Vieira-Sousa E, van Duivenvoorde LM, Fonseca JE, Lories RJ, Baeten DL. 2015 “Review: animal models as a tool to dissect pivotal pathways driving spondyloarthritis” , Arthritis Rheumatol. 67, 2813-27. (View article)